- Advanced search
- Immuno Portal
- Malaria Portal
clindamycin is an approved drug (FDA (1970))
Compound class: Synthetic organic
Comment: Clindamycin is a semisynthetic lincosamide antibacterial with broad-spectrum activity. The compound also has antimalarial activity.
Clindamycin is one of the key access group antibacterials on the World Health Organization's Model List of Essential Medicines (link provided in the Classification table, under the Summary tab below).
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.
|Summary of Clinical Use
|Clindamycin is used to treat a wide range of bacterial infections. These include bone and joint infections, gynaecological infections, intra-abdominal infections, lower respiratory infections, septicemia and skin infections. A combined therapy of clindamycin with fosmidomycin to treat uncomplicated P. falciparum malaria shows promising results, progressing to Phase 3 (NCT00214643). It is also used to treat uncomplicated malaria (particularly useful in areas where chloroquine or multidrug-resistant strains of P. falciparum are found) and as an effective treatment for severe malaria, when used as a combination therapy . It should not be used as a monotherapy for malaria treatment due to a delayed antimalarial effect (see MOA for more details).
|Mechanism Of Action and Pharmacodynamic Effects
|Antibacterial MMOA is reversible binding to the 50S ribosomal subunits to prevent peptide-bond formation by sterically blocking A-site tRNA positioning at the peptidyl-transferase centre (PTC) and thereby inhibiting bacterial protein synthesis . In Plasmodium, pharmacological concentrations of the compound kill the parasite in the lifecycle after treatment starts. It is thought that clindamycin inhibits the production of proteins encoded by the apicoplast genome, leading to a subsequent loss of apicoplast function and a possible explanation for the delayed antimalarial effect .
|Clinical Trial ID
|Efficacy of Fosmidomycin-Clindamycin for Treating Malaria in Gabonese Children
|Phase 3 Interventional
|Albert Schweitzer Hospital
For extended ADME data see the following: